Natco Pharma (NSE:NATCOPHARM) EPS (Basic): ₹79.20 (TTM As of Mar. 2026)


NSE:NATCOPHARM Natco Pharma Ltd NSE:NATCOPHARM
87 GF Score
Price ₹903.70
GF Value ₹940.89
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is Natco Pharma EPS (Basic)?

Natco Pharma NSE:NATCOPHARM +1.13% 87 EPS (Basic) is ₹79.20 as of Mar. 2026. GuruFocus rates NSE:NATCOPHARM with a GF Score™ of 87/100 and a GF Value™ of ₹940.89 (Fairly Valued). The stock has 2 warning signs investors should review.

Natco Pharma's basic earnings per share (Basic EPS) for the three months ended in Mar. 2026 was ₹14.96. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Mar. 2026 was ₹79.20.

Natco Pharma's EPS (Diluted) for the three months ended in Mar. 2026 was ₹14.96. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was ₹79.20.

Natco Pharma's EPS without NRI for the three months ended in Mar. 2026 was ₹14.96. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was 79.20.

During the past 12 months, Natco Pharma's average EPS without NRIGrowth Rate was -24.80% per year. During the past 3 years, the average EPS without NRI Growth Rate was 26.40% per year. During the past 5 years, the average EPS without NRI Growth Rate was 51.10% per year. During the past 10 years, the average EPS without NRI Growth Rate was 16.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Natco Pharma's highest 3-Year average EPS without NRI Growth Rate was 134.00% per year. The lowest was -38.00% per year. And the median was 17.90% per year.

Natco Pharma  (NSE:NATCOPHARM) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Natco Pharma EPS (Basic) Related Terms

Natco Pharma EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Natco Pharma's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Natco Pharma EPS (Basic) Chart

Natco Pharma Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
EPS (Basic)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 9.32 39.18 77.34 105.26 79.20

Natco Pharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 22.70 26.84 28.94 8.46 14.96
NSE:NATCOPHARM
87GF Score
Natco Pharma Ltd NSE:NATCOPHARM
EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Natco Pharma EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Natco Pharma's Basic EPS for the fiscal year that ended in Mar. 2026 is calculated as

Basic EPS (A: Mar. 2026 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(14185-0)/179.104
=79.20

Natco Pharma's Basic EPS for the quarter that ended in Mar. 2026 is calculated as

Basic EPS (Q: Mar. 2026 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(2679-0)/179.078
=14.96

EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹79.20

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of ₹79.20 mean?
Natco Pharma (NSE:NATCOPHARM) has a EPS (Basic) of ₹79.20 as of Mar. 2026. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Natco Pharma and its competitors.
Is Natco Pharma's EPS (Basic) too high?
Natco Pharma's current EPS (Basic) is ₹79.20. Overall, Natco Pharma has a GF Score™ of 87/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Natco Pharma's EPS (Basic) compare to ZTS?
Natco Pharma's EPS (Basic) of ₹79.20 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Drug Manufacturers company?
A good EPS (Basic) depends on the Drug Manufacturers industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Natco Pharma and its competitors. Natco Pharma's current EPS (Basic) is ₹79.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Natco Pharma stock overvalued right now?
Based on GuruFocus' analysis, Natco Pharma (NSE:NATCOPHARM) is currently considered Fairly Valued. The stock's GF Value™ is ₹940.89, compared to a current price of ₹903.70 — trading 4% below its estimated fair value. The current EPS (Basic) is ₹79.20. Natco Pharma's overall GF Score™ is 87/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For Natco Pharma (NSE:NATCOPHARM), the current EPS (Basic) is ₹79.20 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Natco Pharma (NSE:NATCOPHARM) Overvalued in 2026?

Based on GuruFocus' analysis, Natco Pharma stock appears to be undervalued. The current stock price of ₹903.70 is trading 4% below its estimated GF Value™ of ₹940.89. GuruFocus considers Natco Pharma to be Fairly Valued.

Key valuation signals for NSE:NATCOPHARM:

  • EPS (Basic): ₹79.20
  • GF Value™: ₹940.89 vs. price of ₹903.70 (4% below fair value)
  • GF Score™: 87/100 with 2 warning signs

No single metric tells the full story. See the NSE:NATCOPHARM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Natco Pharma Business Description

Other Exchanges 524816:India
Address Road No. 2, NATCO House, Banjara Hills, Hyderabad, TG, IND, 500034
Natco Pharma Ltd is a drug manufacturing company. Natco aims to make specialty medicines accessible to all by manufacturing niche pharmaceutical products backed by its research and development capabilities. While the vast majority of the company's revenue is generated in India, the company looks internationally for growth opportunities. The company maintains a presence in Oncology and Hepatology treatment areas. Natco's active pharmaceutical ingredient segment APIs forms a core part of the company's business. The company operates in two different business segments: pharmaceuticals and agrochemicals. It derives maximum revenue from Pharmaceuticals Segment.
87GF Score

Get the complete analysis for NSE:NATCOPHARM

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹903.70
Price
₹940.89
GF Value